Practitioner Resources, Provider Manual & Video
Newborn Screening saves babies...one foot at a time. Save Babies Through Screening Foundation developed this educational film to share experiences of parents and expert opinions regarding the newborn screening process. It contains information that could save a baby's life.
Internet Case Management (iCMS) Provider Trainings
Order Filter Papers and Other Supplies
Call PerkinElmer Genetics automated supply line at 1-866-463-6436, extension 360
PerkinElmer Genetics fax number is 412-220-0785
Critical Congenital Heart Defect
The Newborn Screening and Follow-up Program completes follow-up activities related to critical congenital heart defects (CCHD). Every infant born in Pennsylvania should receive a CCHD screening between 24-48 hours of life. The below document includes important information for submitters related to: timing of the pulse ox screen, screening tips, screening protocol for well-baby nurseries and NICUs, reporting requirements, CCHD coordinator responsibilities and FAQs.
Neonatal Abstinence Syndrome
Newborn screening dashboards are updated every morning at 6 am. They include data collected over multiple years. For each chart, you can choose to view the data for a specific year or compare data across calendar years.
Note: Dashboards do not load properly in Internet Explorer. It is recommended to use Chrome, Edge or Firefox to view a dashboard.
Cystic Fibrosis (CF) Dashboard
The Cystic Fibrosis (CF) Dashboard presents clinical data collected by the Division of Newborn Screening & Genetics as part of the newborn screening and confirmatory testing done for CF in Pennsylvania. It shows the number of babies and dried-blood spot specimens screened for CF, results of the screening, number of babies referred to treatment centers for next level of confirmatory testing, number of confirmed cases, and prevalence of CF in terms of gender, race, ethnicity and location (county and zip code). It also provides timeliness data from the time a baby is born to when they are diagnosed with CF and when the treatment is started. For questions, contact Division of Newborn Screening and Follow-up Program at 717-783-8143.